187 related articles for article (PubMed ID: 5935707)
21. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
Jeppsson S; Gershagen S; Johansson ED; Rannevik G
Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
[TBL] [Abstract][Full Text] [Related]
22. Analysis of bleeding patterns and resumption of fertility following discontinuation of a long acting injectable contraceptive.
Gardner JM; Mishell DR
Fertil Steril; 1970 Apr; 21(4):286-91. PubMed ID: 5508497
[TBL] [Abstract][Full Text] [Related]
23. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
[TBL] [Abstract][Full Text] [Related]
24. Treatment of breast cancer with medroxyprogesterone acetate.
Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
[TBL] [Abstract][Full Text] [Related]
25. The use of quinesterol for the control of vaginal bleeding irregularities caused by DMPA.
Parker RA; McDaniel EB
Contraception; 1980 Jul; 22(1):1-7. PubMed ID: 7418403
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic study of different doses of Depo Provera.
Fotherby K; Koetsawang S; Mathrubutham M
Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
[TBL] [Abstract][Full Text] [Related]
27. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
[TBL] [Abstract][Full Text] [Related]
28. [Contraception with injectable long-acting preparation depo-provera].
Prilepskaia VN; Kondrikov NI; Tagieva TT
Akush Ginekol (Mosk); 1995; (3):7-10. PubMed ID: 7653732
[TBL] [Abstract][Full Text] [Related]
29. Effect of switching with oral contraceptives.
Wassef SA; Sami G; Hamid EA
Egypt Popul Fam Plann Rev; 1970 Jun; 3(1):77-93. PubMed ID: 12254511
[TBL] [Abstract][Full Text] [Related]
30. A preliminary pharmacological trial of the monthly injectable contraceptive cycloprovera.
Fotherby K; Benagiano G; Toppozada HK; Abdel-Rahman A; Navaroli F; Arce B; Ramos-Cordero R; Gual C; Landgren BM; Johannisson E
Contraception; 1982 Mar; 25(3):261-72. PubMed ID: 6210485
[TBL] [Abstract][Full Text] [Related]
31. [Concentration of estrone, estradiol and estriol in the blood of pregnant sheep after induction of estrus with chlormadinone acetate and medroxyprogesterone acetate].
Halagan J; Arendarcik J
Vet Med (Praha); 1976 Sep; 21(9):551-6. PubMed ID: 66795
[TBL] [Abstract][Full Text] [Related]
32. The effect of transdermal oestradiol on bleeding pattern, hormonal profiles and sex steroid receptor distribution in the endometrium of Norplant users.
Boonkasemsanti W; Reinprayoon D; Pruksananonda K; Niruttisard S; Triratanachat S; Leepipatpaiboon S; Wannakrairot P
Hum Reprod; 1996 Oct; 11 Suppl 2():115-23. PubMed ID: 8982753
[TBL] [Abstract][Full Text] [Related]
33. Depo-Provera--ethical issues in its testing and distribution.
Potts M; Paxman JM
J Med Ethics; 1984 Mar; 10(1):9-20. PubMed ID: 6231379
[TBL] [Abstract][Full Text] [Related]
34. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.
Fotherby K; Saxena BN; Shrimanker K; Hingorani V; Takker D; Diczfalusy E; Landgren BM
Fertil Steril; 1980 Aug; 34(2):131-9. PubMed ID: 7409232
[TBL] [Abstract][Full Text] [Related]
35. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
[TBL] [Abstract][Full Text] [Related]
36. [Prolonged-action contraceptives].
Alipov VI; Korkhov VV
Akush Ginekol (Mosk); 1987 Sep; (9):7-8. PubMed ID: 3322079
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
[TBL] [Abstract][Full Text] [Related]
38. Long-acting steroids provide new options.
Netw Res Triangle Park N C; 1988; 9(3):1-3, 7. PubMed ID: 12315656
[TBL] [Abstract][Full Text] [Related]
39. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
40. Estrogenic activity in women receiving an injectable progestogen for contraception.
Mishell DR; Kharma KM; Thorneycroft IH; Nakamura RM
Am J Obstet Gynecol; 1972 Jun; 113(3):372-6. PubMed ID: 4637029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
